TITLE

Nitrendipine in the Treatment of Mild to Moderate Hypertension

AUTHOR(S)
Moser, Marvin
PUB. DATE
January 1988
SOURCE
Angiology;Jan1988 Part 2, Vol. 39 Issue 1, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Studies have demonstrated that the calcium entry blockers are effective anti-hypertensive drugs, both in severe and in mild to moderately severe hypertension.1.2 Animal and human data have also demonstrated that the reduction in vascular resistance that occurs when these agents are administered not only results in lowered blood pressure but in a reduction in left ventricular mass.3,4 Most reports regarding efficacy of the calcium blockers have concerned themselves with the three available compounds in the United States, nifedipine, diltiazem and verapamil.5 Recent studies with nitrendipine, a new calcium entry blocker related chemically to nifedipine, indicate that it may also be an effective antihypertensive agent, with the advantages of the rapid onset of action of nifedipine and a long duration of action similar to verapamil.6 In addition, there is evidence that nitrendipine may reduce pre-load, in addition to afterload, with a minimal effect upon heart rate.
ACCESSION #
16353268

 

Related Articles

  • Nitrendipine Monotherapy in Severe Hypertension. Mroczek, William J.; Burris, James F. // Angiology;Jan1988 Part 2, Vol. 39 Issue 1, p81 

    Nitrendipine is a new dihydropyridine derivative developed specifically for the treatment of hypertension. Oral nitrendipine was administered to twelve patients with severe hypertension (diastolic blood pressure greater than 114 mm/Hg). All antihypertensive drugs were discontinued at least 72...

  • Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Flynn, Joseph T.; Pasko, Deborah A. // Pediatric Nephrology;Dec2000, Vol. 15 Issue 3/4, p302 

    The calcium channel blockers (CCBs) are a diverse group of antihypertensive medications with variable pharmacokinetics and clinical effects. Although CCBs have been widely applied to the treatment of hypertensive children, data regarding the pharmacokinetics,efficacy and safety of these agents...

  • Controlling refractory BP.  // Cortlandt Forum;Dec2007, Vol. 20 Issue 12, p12 

    The article provides information about the new drug Azor manufactured by Daiichi Sankyo Co., indicated for hypertension. The drug's pharmacologic class is an antihypertensive with calcium channel blocker + angiotensin II receptor blocker. It may be used as add-on therapy for patients...

  • Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate. Kereiakes, Dean J.; Neutel, Joel M.; Punzi, Henry A.; Jianbo Xu; Lipka, Leslie J.; Dubiel, Robert // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 4, p361 

    BACKGROUND: Most patients with stage 2 hypertension require two or more antihypertensive agents in order to achieve the BP goals recommended in current treatment guidelines. Accordingly, combinations of two drugs with different mechanisms of antihypertensive action are widely used. OBJECTIVE:...

  • Secondary stroke prophylaxis: ARB bests calcium antagonist.  // Formulary;May2005, Vol. 40 Issue 5, p157 

    Discusses a study which suggested that the angiotensin receptor blocker (ARB) eprosartan is superior to the calcium antagonist nitrendipine in secondary stroke prophylaxis in patients with hypertension. Findings reported by Dr. Hans-Chrisdan Diener at the American Stroke Association's...

  • Renal and hemodynamic responses to bumetanide in hypertension: Effects of nitrendipine. Wilcox, Christopher S.; Loon, Nicholas R.; Ameer, Barbara; Limacher, Marian C. // Kidney International;Oct1989, Vol. 36 Issue 4, p719 

    The effects of a calcium antagonist on the response to a loop diuretic were tested in eight hypertensive patients while they received 120 mmol · 24 hr-1 of dietary Na. Nitrendipine (N; 20 mg) or placebo (P) was administered twice daily for five days and bumetanide (B; 1 mg i.v.) for the last...

  • SECTION 2: CARDIOVASCULAR SYSTEM.  // MPR - Pharmacist's Edition;Summer2010, Vol. 4 Issue 2, p3 

    The article provides information on cardiovascular agents for the treatment of hypertension. These antihypertensive drugs that would help in reducing the cardiovascular morbidity and mortality include the diuretics, the Angiotensin Converting Enzyme (ACE) inhibitors, and the calcium channel...

  • What we really need to do to reduce cardiovascular events in hypertensive patients. Ong, H. T. // Romanian Journal of Medical Practice;2007, Vol. 2 Issue 4, p283 

    The article focuses on a study which examined ways of reducing cardiovascular events in patients with hypertension. The review of 13 comparative antihypertensive drug trials reveals no significant differences in the cardiovascular protective effects of diuretics, beta-blockers, calcium channel...

  • Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier. Paris, Daniel; Bachmeier, Corbin; Patel, Nikunj; Quadros, Amita; Volmar, Claude-Henry; Laporte, Vincent; Ganey, Jim; Beaulieu-Abdelahad, David; Ait-Ghezala, Ghania; Crawford,, Fiona; Mul, Michael J. // Molecular Medicine;Mar/Apr2011, Vol. 17 Issue 3/4, p149 

    Several large population-based or clinical trial studies have suggested that certain dihydropyridine (DHP) L-type calcium channel blockers (CCBs) used for the treatment of hypertension may confer protection against the development of Alzheimer disease (AD). However, other studies with drugs of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics